| Mepha Pharma AG - Buprenorphin-Mepha 52.5 ug/h, Transdermale Pflaster | | 65809 | | 02 | | Buprenorphin-Mepha 52.5 ug/h | | Transdermale Pflaster | | N02AE01 | | Buprenorphin | | 19.05.2015 | | |
| | Composition | | buprenorphinum 30 mg, oleylis oleas, povidonum K 90, acidum laevulinicum, acrylates et vinylis acetatis polymerisatum (vernetzt), poly(ethylenis terephthalas), acrylates et vinylis acetatis polymerisatum (nicht vernetzt), Trägermaterial: poly(ethylenis terephthalas), ad praeparationem pro 37.5 cm², cum liberatione 52.5 µg/h. | | Packungsbestandteile | | Transdermale Pflaster | | | | | | | | Principe actif | Concentr. |
|---|
| Buprenorphine | 30 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Buprenorphine | 30 mg |
|
| |
|
